Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology.

COVID-19 PREMs SARS-CoV-2 cancer patients patients’ perspective survey

Journal

Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748

Informations de publication

Date de publication:
2022
Historique:
received: 07 12 2021
accepted: 24 12 2021
entrez: 17 2 2022
pubmed: 18 2 2022
medline: 18 2 2022
Statut: epublish

Résumé

The SARS-CoV-2 spread has impacted Healthcare systems. COVID-19 pandemic has had consequences for patients with cancer, being associated with delays in diagnosis, in treatment And follow-up care, increase in overall infection rates and higher mortality. A survey on COVID-19 and a vaccination-questionnaire were developed at different times of the outbreak, to evaluate cancer patient-reported experience measures (PREMs) on the policies implemented to reduce the infection from SARS-CoV-2 and on the timing and methods of COVID-19 vaccination. The survey was distributed to all patients accessing the Institute during the "first-wave" Of the pandemic, evaluating patients' concerns about the pandemic, the pandemics' consequences on their cancer care, and their perception Of the measures adopted to limit the infection spread. The vaccination-questionnaire was proposed to 10% of the first 5297 cancer patients vaccinated with two doses of the Pfizer-BioNTechCOVID-19 vaccine. This questionnaire aimed at assessing the degree Of satisfaction with the Institutional vaccination campaign and vaccination-related adverse events. From May 18th 2020 to June 15th 2020 the survey was completed by 3238 patients. Most of the responders expressed concern on the pandemic yet acknowledging their oncological disease as a priority. Measures implemented were appreciated by patients. Telemedicine was positively evaluated and the absence of the caregiver during the visit did not determine discomfort for two thirds of patients. From March 6th 2021 to May 8th 2021 the vaccination-questionnaire was completed by 357 patients. The 98.8% were satisfied with the vaccination campaign. No serious vaccination-correlated adverse events were reported. No patient had to delay/discontinue chemotherapy due to vaccination. PREMs during COVID-19 pandemic and related vaccination can provide important information to help reorganization of the health care systems for cancer care. Patients' feedback on the organizational changes implemented in the emergency period are essential for healthcare improvement and to help informed choices that are consistent with patients' needs.

Identifiants

pubmed: 35173420
doi: 10.2147/PPA.S351771
pii: 351771
pmc: PMC8841696
doi:

Types de publication

Journal Article

Langues

eng

Pagination

353-362

Informations de copyright

© 2022 Caccese et al.

Déclaration de conflit d'intérêts

Dr Sara Lonardi reports grants and personal fees from Amgen, Merck Serono Roche, Lilly, Astra Zeneca, and Bristol-Myers Squibb, grants from Bayer, and personal fees from Incyte, Daiichi-Sankyo, Servier, MSD, Pierre-Fabre, and GSK, outside the submitted work. Dr Antonella Brunello reports personal fees and travel expenses from and advisory board for Pharmamar, and personal fees from Glaxo Smith Kline, outside the submitted work. The authors report no other potential conflicts of interest for this work.

Références

Appl Clin Inform. 2016 Apr 20;7(2):238-47
pubmed: 27437037
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Cancers (Basel). 2020 Aug 20;12(9):
pubmed: 32825295
JCO Glob Oncol. 2020 Oct;6:1494-1509
pubmed: 33017179
Cancer Med. 2020 Dec;9(24):9193-9204
pubmed: 33219746
Front Med (Lausanne). 2020 Nov 27;7:594610
pubmed: 33330558
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Ann Oncol. 2021 May;32(5):579-581
pubmed: 33582237
Future Oncol. 2021 Nov;17(31):4071-4079
pubmed: 34337969
J Geriatr Oncol. 2020 Jun;11(5):761-763
pubmed: 32327321
ESMO Open. 2021 Apr;6(2):100100
pubmed: 33819751
J Med Internet Res. 2020 Jul 6;22(7):e19322
pubmed: 32568721
Patient Prefer Adherence. 2017 Sep 27;11:1671-1676
pubmed: 29033554
Eur J Cancer. 2020 Aug;135:159-169
pubmed: 32580131
J Geriatr Oncol. 2020 Nov;11(8):1349-1351
pubmed: 32482554
J Clin Oncol. 2020 Oct 1;38(28):3248-3251
pubmed: 32749939
Adm Policy Ment Health. 2014 Jul;41(4):434-46
pubmed: 22829193
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Eur J Cancer. 2020 Sep;136:132-139
pubmed: 32683273
Int J Qual Health Care. 2017 Jun 1;29(3):314-326
pubmed: 28339923
JAMA Oncol. 2020 Nov 1;6(11):1698-1699
pubmed: 32672821
Eur J Cancer. 2021 Apr;147:120-127
pubmed: 33647547
Oncologist. 2021 Feb;26(2):e336-e337
pubmed: 33044758
Clin Transl Oncol. 2020 Dec;22(12):2364-2368
pubmed: 32449128
PLoS One. 2019 Aug 30;14(8):e0221848
pubmed: 31469865
Curr Rheumatol Rev. 2015;11(1):1-7
pubmed: 26002458
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
Oncologist. 2020 Jul;25(7):e1131
pubmed: 32307803
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Med Care Rev. 1992 Winter;49(4):455-84
pubmed: 10123083
Front Oncol. 2021 Jun 28;11:669786
pubmed: 34262861
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J R Coll Physicians Edinb. 2012;42(4):301-5
pubmed: 23240114
Ann Surg. 2020 Aug;272(2):e81-e83
pubmed: 32675505
Eur J Cancer. 2021 Aug;153:260-264
pubmed: 34183225

Auteurs

Mario Caccese (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Silvia Imbevaro (S)

General Directorate, Accreditation and Acknowledgment Unit, Veneto Institute of Oncolog IOV - IRCCS, Padua, Italy.

Alessandra Feltrin (A)

Health Department, Psycho-Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Daniela Costardi (D)

Scientific Directorate, Patient Education and Empowerment, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Nadia Giordano (N)

Department of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Maristella Maran (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Rosalba Martino (R)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Ketti Ottolitri (K)

Health Department, Clinical Risk Office, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Malihe Shams (M)

Health Department, Psycho-Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Federica Vascon (F)

Department of Imaging and Health Physics, Radiotherapy Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Anna Roma (A)

Department of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Antonella Galiano (A)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Marco Maruzzo (M)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Dario Marino (D)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Giuseppe Lombardi (G)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Sara Lonardi (S)

Department of Oncology, Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Antonella Brunello (A)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Vittorina Zagonel (V)

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.

Classifications MeSH